Traws Pharma Scales Up Dual-Strike Antiviral for Hantavirus, Ebola with BSL-3/4 Studies
TRAW•Traws Pharma’s novel combination antiviral depletes host nucleotides and forces lethal incorporation of nucleoside mimics to target Hantavirus, Ebola and Lassa with lower IC90 requirements. The company is scaling non-clinical BSL-3/4 studies and partnering with CDC, NAFDAC and AMA for emergency manufacturing and global stockpiling.
1. Novel Antiviral Mechanism
Traws Pharma’s proprietary combination utilizes a dual-strike approach: one agent depletes host nucleotide pools while the other forces viral RNA-dependent RNA polymerase to incorporate nucleoside mimics. This synergy lowers the IC90 needed to halt replication of Hantavirus, Ebola and Lassa viruses, enabling high potency at reduced doses.
2. Preclinical Development Progress
The company is advancing the combination in validated animal models under Biosafety Level 3 and 4 conditions, leveraging prior human safety data for each component to accelerate pharmacology and toxicology assessment. These studies aim to confirm efficacy and safety profiles before initiating first-in-human trials.
3. Regulatory Partnerships and Scale-Up
Traws Pharma is engaging with the US CDC, Nigeria’s NAFDAC and the African Medicines Agency to fast-track regulatory approvals, emergency manufacturing scale-up and regional production. Strategic Nigerian partnerships will support local drug product manufacturing and streamline stockpiling for immediate outbreak response.
